Radiology, HUH Diagnostic Center, University of Helsinki and Helsinki University Hospital, P.O Box 140, 00029, HUS, Finland.
Department of Breast Surgery, Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, P.O Box 281, 00029, HUS, Finland.
Eur J Surg Oncol. 2022 Jan;48(1):67-72. doi: 10.1016/j.ejso.2021.10.020. Epub 2021 Oct 27.
This study aims to compare the feasibility of VAE and BLES in the treatment of intraductal papillomas.
Patients with a suspected intraductal papilloma who underwent a BLES or a VAE procedure were included in this retrospective study. The BLES procedures were performed between November 2011 and June 2016 and the VAE procedures between May 2018 and September 2020 at the Department of Radiology of Helsinki University Hospital (HUH). The procedures were performed with an intent of complete removal of the lesions.
In total, 72 patients underwent 78 BLES procedures and 95 patients underwent 99 VAE procedures. Altogether 52 (60%) papillomas with or without atypia were completely removed with VAE, whereas 24 (46%) were completely removed with BLES, p = 0.115. The median radiological size of the high-risk lesions completely removed with BLES was 6 mm (4-12 mm), whereas with VAE it was 8 mm (3-22 mm), p = 0.016. Surgery was omitted in 90 (94.7%) non-malignant breast lesions treated with VAE and in 66 (90.4%) treated with BLES, p = 0.368.
Both VAE and BLES were feasible in the treatment of intraductal papillomas. In most non-malignant lesions surgery was avoided, but VAE was feasible in larger lesions than BLES. However, follow-up ultrasound was needed more often after VAE. The histopathologic assessment is more reliable after BLES, as the lesion is removed as a single sample.
本研究旨在比较 VAE 和 BLES 治疗导管内乳头状瘤的可行性。
本回顾性研究纳入了在赫尔辛基大学医院(HUH)放射科行 BLES 或 VAE 治疗的疑似导管内乳头状瘤患者。BLES 手术于 2011 年 11 月至 2016 年 6 月进行,VAE 手术于 2018 年 5 月至 2020 年 9 月进行。手术目的为完全切除病变。
共有 72 例患者行 78 次 BLES 手术,95 例患者行 99 次 VAE 手术。共 52 例(60%)伴或不伴非典型增生的乳头状瘤通过 VAE 完全切除,而 24 例(46%)通过 BLES 完全切除,p=0.115。BLES 完全切除的高危病变的中位放射学大小为 6 毫米(4-12 毫米),而 VAE 为 8 毫米(3-22 毫米),p=0.016。90 例(94.7%)行 VAE 治疗的非恶性乳腺病变和 66 例(90.4%)行 BLES 治疗的非恶性乳腺病变免于手术,p=0.368。
VAE 和 BLES 均可行导管内乳头状瘤的治疗。在大多数非恶性病变中,可避免手术,但 VAE 适用于比 BLES 更大的病变。然而,VAE 后更常需要进行超声随访。BLES 切除的标本为单个样本,因此组织病理学评估更可靠。